Phaseline

Companies › Vifor Fresenius Medical Care Renal Pharma

Vifor Fresenius Medical Care Renal Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Aug 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Difelikefalin
Kappa opioid receptor agonist
OPRK1Phase 2PruritusAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06593392DifelikefalinPhase 2PruritusGenitourinaryAug 2029

Targets

OPRK1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Johnson & Johnson (Janssen) Alkermes Tioga Pharmaceuticals

Companies built like this

Tioga Pharmaceuticals Kira Pharmacenticals (US) Veloxis Pharmaceuticals Juro Sciences Vaneltix Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.